N-acetylgalactosamino Dendron Clearing Agent for Pretargeted Radioimmunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pretargeted radioimmunotherapy methods face challenges in achieving efficient tumor targeting and rapid clearance of radiolabeled small molecules from non-tumor tissues, leading to suboptimal tumor-to-background ratios and limited therapeutic efficacy due to high background activity and toxicity.
Innovation Solution
The development of novel N-acetylgalactosamino dendron-clearing agents that facilitate rapid blood clearance of radiolabeled bispecific antibodies and improve the therapeutic index by forming complexes with circulating antibodies, allowing for enhanced tumor targeting and reduced normal tissue uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If radiolabeled small molecules are used for pretargeted radioimmunotherapy, then blood clearance is rapid and background is low, but tumor specificity is poor due to low affinity for target
Solution Approach 1:
The system divides the targeting function into two separate components: a high-affinity antibody that provides specific tumor targeting, and a radiolabeled small molecule hapten that provides rapid blood clearance. The antibody binds to the hapten at the tumor site with high affinity, while the small size of the radiolabeled hapten enables rapid clearance from blood, resolving the contradiction between fast clearance and high specificity.
2Speed
If small peptide and metal chelate haptens are used in PRIT systems, then blood clearance is improved, but whole-body retention is significant resulting in high background activity
Solution Approach 1:
The patent introduces a clearing agent as an intermediary substance that binds to circulating radiolabeled haptens in the blood and facilitates their rapid removal from the body. This intermediary mechanism enhances blood clearance and reduces whole-body retention of radiolabeled haptens, thereby lowering background activity without compromising the high-affinity binding at the tumor site.
3Reliability
If antibodies are used for targeted delivery, then tumor targeting is achieved, but tumor-to-background ratio is low due to long half-life in blood
Solution Approach 1:
The system segments the therapeutic agent into two parts with different pharmacokinetic properties: a large antibody component that provides long circulation half-life and high tumor targeting affinity, and a small radiolabeled hapten component that can be rapidly cleared from blood. The antibody accumulates at the tumor site over time, while unbound radiolabeled hapten in the blood is quickly removed, achieving both high tumor targeting and low background.
4Speed
If antibody fragments are used, then blood clearance is faster, but kidney and liver uptake is high
Solution Approach 1:
The clearing agent acts as an intermediary that selectively binds to radiolabeled haptens in the bloodstream and facilitates their removal through pathways that avoid high uptake in kidney and liver. This intermediary mechanism enables fast blood clearance while minimizing toxic accumulation in sensitive organs.
Data Source
AI summary
The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.